ACPI

Reported Uses

• NOTE: see Herb & Supplement Effectiveness Rating Definitions table
• ADHD [Insufficient Evidence]
• age-related macular degeneration [Possibly Ineffective]
• allergic rhinitis prevention [Insufficient Evidence]
• Alzheimer dz [Insufficient Evidence]
• angina [Possibly Ineffective]
• aphthous ulcer (canker sores) [Insufficient Evidence]
• ARDS [Insufficient Evidence]
• asthma [Insufficient Evidence]
• atherosclerosis [Possibly Ineffective]
• athletic performance [Insufficient Evidence]
• atopic dermatitis (eczema) [Possibly Ineffective]
• atopic dz [Insufficient Evidence]
• atrial fibrillation [Possibly Ineffective]
• autism spectrum disorder [Insufficient Evidence]
• autoimmune thyroiditis prevention [Insufficient Evidence]
• bipolar disorder [Insufficient Evidence]
• bone loss, renal transplant-related [Insufficient Evidence]
• borderline personality disorder [Insufficient Evidence]
• bronchopulmonary dysplasia [Possibly Ineffective]
• burns [Insufficient Evidence]
• CABG [Insufficient Evidence]
• cachexia, cancer-related [Possibly Effective]
• cancer prevention [Insufficient Evidence]
• cardiovascular dz prevention [Insufficient Evidence]
• cataracts [Insufficient Evidence]
• cerebrovascular dz prevention [Possibly Ineffective]
• cirrhosis [Insufficient Evidence]
• CKD [Insufficient Evidence]
• cognitive decline, age-related [Insufficient Evidence]
• cognitive function [Possibly Ineffective]
• cognitive impairment, mild [Insufficient Evidence]
• colorectal CA [Insufficient Evidence]
• COPD [Insufficient Evidence]
• COVID-19 [Insufficient Evidence]
• Crohn dz [Insufficient Evidence]
• cystic fibrosis [Insufficient Evidence]
• dementia [Insufficient Evidence]
• depression [Insufficient Evidence]
• developmental coordination disorder [Insufficient Evidence]
• diabetes mellitus [Likely Ineffective]
• diabetic nephropathy [Insufficient Evidence]
• diabetic neuropathy [Insufficient Evidence]
• diabetic retinopathy [Insufficient Evidence]
• dry eye dz [Insufficient Evidence]
• dyslexia [Insufficient Evidence]
• dyslipidemia [Insufficient Evidence]
• dyslipidemia, HIV/AIDS-related [Possibly Effective]
• dysmenorrhea [Possibly Effective]
• endometriosis [Insufficient Evidence]
• epilepsy [Insufficient Evidence]
• exercise-induced muscle soreness [Insufficient Evidence]
• food allergies [Insufficient Evidence]
• frailty [Insufficient Evidence]
• gingivitis [Insufficient Evidence]
• glaucoma [Insufficient Evidence]
• heart failure [Possibly Effective]
• heart transplant [Insufficient Evidence]
• hemodialysis graft dysfxn [Insufficient Evidence]
• HIV/AIDS [Insufficient Evidence]
• H. pylori infection [Possibly Ineffective]
• HTN [Possibly Effective]
• HTN, cyclosporine-induced [Insufficient Evidence]
• HTN, pregnancy-induced [Possibly Ineffective]
• IgA nephropathy [Possibly Effective]
• hypertriglyceridemia [Effective]
• impaired glucose tolerance [Insufficient Evidence]
• infant development [Insufficient Evidence]
• insomnia [Insufficient Evidence]
• intrauterine growth restriction [Insufficient Evidence]
• joint pain [Insufficient Evidence]
• lung CA [Insufficient Evidence]
• Lyme dz [Insufficient Evidence]
• male infertility [Insufficient Evidence]
• mastalgia [Possibly Ineffective]
• melanoma [Insufficient Evidence]
• menopausal sx [Insufficient Evidence]
• metabolic effects, antipsychotic-induced [Insufficient Evidence]
• migraine prophylaxis [Insufficient Evidence]
• miscarriage prevention, antiphospholipid syndrome-assoc. [Insufficient Evidence]
• multiple sclerosis [Possibly Ineffective]
• muscle strength [Insufficient Evidence]
• nausea/vomiting, gastroenteritis-related [Possibly Effective]
• nephrolithiasis [Insufficient Evidence]
• nephropathy, contrast-induced [Insufficient Evidence]
• nephrotoxicity, cyclosporine-induced [Possibly Effective]
• nonalcoholic fatty liver dz [Possibly Effective]
• obesity [Insufficient Evidence]
• oral mucositis [Insufficient Evidence]
• osteoarthritis [Possibly Ineffective]
• osteoporosis [Insufficient Evidence]
• Parkinson dz [Insufficient Evidence]
• periodontitis [Insufficient Evidence]
• peripheral arterial dz [Insufficient Evidence]
• peripheral neuropathy, chemo-induced [Insufficient Evidence]
• phenylketonuria [Insufficient Evidence]
• pneumonia prevention [Insufficient Evidence]
• polycystic ovary syndrome [Insufficient Evidence]
• polymyalgia rheumatica prevention [Insufficient Evidence]
• postmenopausal conditions [Insufficient Evidence]
• postop fistula [Insufficient Evidence]
• postop infection [Insufficient Evidence]
• postop recovery [Insufficient Evidence]
• postpartum depression [Insufficient Evidence]
• post-traumatic stress disorder [Insufficient Evidence]
• pre-eclampsia [Possibly Ineffective]
• premature labor prevention [Insufficient Evidence]
• prematurity [Insufficient Evidence]
• pressure ulcer [Insufficient Evidence]
• prostate CA [Insufficient Evidence]
• pruritus [Insufficient Evidence]
• psoriasis [Insufficient Evidence]
• psychosis [Possibly Ineffective]
• PTCA restenosis prevention [Possibly Effective]
• Raynaud phenomenon [Insufficient Evidence]
• renal failure [Insufficient Evidence]
• renal transplant [Possibly Ineffective]
• rheumatoid arthritis [Possibly Effective]
• salicylate intolerance [Insufficient Evidence]
• sarcopenia [Insufficient Evidence]
• schizophrenia [Insufficient Evidence]
• sepsis [Insufficient Evidence]
• sickle cell dz [Insufficient Evidence]
• SLE [Insufficient Evidence]
• stroke prevention [Insufficient Evidence]
• ulcerative colitis [Insufficient Evidence]
• URI [Insufficient Evidence]
• venous thromboembolism prophylaxis [Insufficient Evidence]
• ventricular arrhythmias [Possibly Ineffective]
• vitamin D deficiency [Insufficient Evidence]